Table 1. Characteristics of the study population at baseline.
| All (n=674) | LLV (n=203) | MVR (n=471) | p | |
|---|---|---|---|---|
| Age, years | 44 (34, 52) | 44 (35, 52) | 44 (34, 52) | 0.199 |
| Male, % | 488 (72.4%) | 153 (75.4%) | 335 (71.1%) | 0.258 |
| HBeAg positive, % | 380 (56.7%) | 136 (67.0%) | 244 (52.2%) | 0.000 |
| HBV DNA, log10 IU/L | 5.64 (3.99, 6.90) | 6.11 (4.29, 7.30) | 5.44 (3.85, 6.76) | 0.001 |
| Platelet, 109/L | 153 (108, 191) | 150 (100, 188) | 154 (112, 192) | 0.279 |
| ALT, U/L | 80 (40, 170) | 68 (38, 115) | 89 (40, 188) | 0.003 |
| AST, U/L | 55 (34, 104) | 48 (34, 74) | 59 (34, 121) | 0.002 |
| Bilirubin, mmol/L | 14.9 (11.20, 20.25) | 15.15 (11.60, 20.65) | 14.70 (11.00, 20.10) | 0.373 |
| Albumin, mg/L | 44.70 (42.60, 46.75) | 45.05 (42.98, 47.63) | 44.60 (42.30, 46.40) | 0.016 |
| Cirrhosis, % | 200 (29.7%) | 60 (29.6%) | 140 (29.7%) | 0.965 |
| Treatment-naïve, % | 545 (80.9%) | 158 (77.8%) | 387 (82.2%) | 0.190 |
| Treatment | 0.000 | |||
| First-line drugs, % | 499 (74.0%) | 118 (58.1%) | 381 (80.9%) | |
| Non-first-line drugs, % | 157 (23.3%) | 73 (36.0%) | 84 (17.8%) | |
| Non-first-line drugs combined with first-line drugs, % | 18 (2.7%) | 12 (5.9%) | 6 (1.3%) |
LLV, low-level viremia; MVR, maintained virological response; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase.